PPARA and metabolic dysfunction-associated steatotic liver disease: Additionally, QTB treatment resulted in significant changes in hepatic metabolic signals by increasing the expression of genes like ATGL, PPARα, the short-chain fatty acid receptors (FFAR2 and FFAR3), which contributed in improving liver metabolism and preventing MASLD [36].